Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Granuloma | 1 | 2019 | 45 | 0.640 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2016 | 3 | 0.530 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2016 | 27 | 0.520 |
Why?
|
| Dyspepsia | 1 | 2015 | 10 | 0.510 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 47 | 0.500 |
Why?
|
| Cough | 1 | 2015 | 55 | 0.490 |
Why?
|
| Inflammation | 1 | 2019 | 608 | 0.480 |
Why?
|
| Peptide Hormones | 1 | 2014 | 4 | 0.460 |
Why?
|
| Failure to Thrive | 1 | 2014 | 19 | 0.460 |
Why?
|
| Ghrelin | 1 | 2014 | 29 | 0.450 |
Why?
|
| Methotrexate | 2 | 2024 | 73 | 0.420 |
Why?
|
| Pancreatic Function Tests | 1 | 2012 | 2 | 0.400 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2012 | 3 | 0.400 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 187 | 0.400 |
Why?
|
| Pancreatic Elastase | 1 | 2012 | 16 | 0.390 |
Why?
|
| Pancreas | 1 | 2012 | 71 | 0.390 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 402 | 0.380 |
Why?
|
| Feces | 1 | 2012 | 131 | 0.380 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 601 | 0.330 |
Why?
|
| Adolescent | 9 | 2024 | 6459 | 0.320 |
Why?
|
| Child | 10 | 2024 | 6862 | 0.320 |
Why?
|
| Mesalamine | 2 | 2019 | 12 | 0.310 |
Why?
|
| Colitis, Ulcerative | 2 | 2019 | 52 | 0.300 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 100 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 122 | 0.280 |
Why?
|
| Obesity | 1 | 2014 | 1112 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2024 | 388 | 0.240 |
Why?
|
| Crohn Disease | 1 | 2024 | 90 | 0.210 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 382 | 0.210 |
Why?
|
| Male | 9 | 2024 | 25572 | 0.190 |
Why?
|
| Body Mass Index | 1 | 2024 | 658 | 0.180 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 108 | 0.160 |
Why?
|
| Child, Preschool | 4 | 2019 | 3896 | 0.160 |
Why?
|
| Humans | 11 | 2024 | 50201 | 0.150 |
Why?
|
| Splenomegaly | 1 | 2016 | 11 | 0.130 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2016 | 7 | 0.130 |
Why?
|
| Sulfhydryl Compounds | 1 | 2016 | 15 | 0.130 |
Why?
|
| Portal Vein | 1 | 2016 | 26 | 0.130 |
Why?
|
| Hypertension, Portal | 1 | 2016 | 20 | 0.130 |
Why?
|
| Health Communication | 1 | 2016 | 22 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2016 | 58 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2016 | 84 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2015 | 195 | 0.120 |
Why?
|
| Contrast Media | 1 | 2016 | 186 | 0.120 |
Why?
|
| Infant | 2 | 2014 | 3584 | 0.120 |
Why?
|
| Biopsy | 1 | 2016 | 592 | 0.110 |
Why?
|
| Fasting | 1 | 2014 | 72 | 0.110 |
Why?
|
| Oxygen | 1 | 2016 | 321 | 0.110 |
Why?
|
| Energy Intake | 1 | 2014 | 170 | 0.110 |
Why?
|
| Echocardiography | 1 | 2016 | 390 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 337 | 0.100 |
Why?
|
| Secretin | 1 | 2012 | 3 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1041 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 489 | 0.100 |
Why?
|
| Body Weight | 1 | 2014 | 513 | 0.100 |
Why?
|
| Bezoars | 1 | 2010 | 2 | 0.090 |
Why?
|
| Stomach Diseases | 1 | 2010 | 13 | 0.090 |
Why?
|
| Liver | 1 | 2016 | 1122 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1160 | 0.090 |
Why?
|
| Female | 7 | 2024 | 26829 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 871 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 921 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 5203 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2019 | 1414 | 0.060 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 35 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2024 | 116 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2012 | 6190 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 459 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 70 | 0.040 |
Why?
|
| Remission Induction | 1 | 2017 | 206 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2017 | 432 | 0.030 |
Why?
|
| Hospitalization | 1 | 2019 | 665 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 320 | 0.030 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2010 | 7 | 0.020 |
Why?
|
| Laparotomy | 1 | 2010 | 35 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 239 | 0.020 |
Why?
|
| Stomach | 1 | 2010 | 80 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 660 | 0.020 |
Why?
|